Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

1.

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA.

J Clin Oncol. 2010 Aug 1;28(22):3555-61. doi: 10.1200/JCO.2009.27.5719. Epub 2010 Jun 14. Erratum in: J Clin Oncol. 2010 Nov 10;28(32):4868.

PMID:
20547991
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.

Mukhopadhyay A, Curtin N, Plummer R, Edmondson RJ.

BJOG. 2011 Mar;118(4):429-32. doi: 10.1111/j.1471-0528.2010.02838.x. Epub 2011 Jan 18. Review.

PMID:
21244617
[PubMed - indexed for MEDLINE]
3.

PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.

Carden CP, Yap TA, Kaye SB.

Curr Opin Oncol. 2010 Sep;22(5):473-80. doi: 10.1097/CCO.0b013e32833b5126. Review.

PMID:
20485165
[PubMed - indexed for MEDLINE]
4.

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

Banerjee S, Kaye S.

Curr Oncol Rep. 2011 Dec;13(6):442-9. doi: 10.1007/s11912-011-0193-9. Review.

PMID:
21913063
[PubMed - indexed for MEDLINE]
5.

[Hereditary ovarian cancer. The role of BRCA1 gene dysfunction in response to chemotherapy].

Blecharz P, Karolewski K, UrbaƄski K.

Ginekol Pol. 2011 Mar;82(3):214-20. Review. Polish.

PMID:
21735691
[PubMed - indexed for MEDLINE]
6.

Gene expression and prognostic significance in ovarian cancer.

Tammela J, Odunsi K.

Minerva Ginecol. 2004 Dec;56(6):495-502. Review.

PMID:
15729202
[PubMed - indexed for MEDLINE]
7.

Advances in the management of epithelial ovarian cancer.

Berkenblit A, Cannistra SA.

J Reprod Med. 2005 Jun;50(6):426-38. Review.

PMID:
16050567
[PubMed - indexed for MEDLINE]
8.

Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.

Ratner ES, Sartorelli AC, Lin ZP.

Curr Opin Oncol. 2012 Sep;24(5):564-71. doi: 10.1097/CCO.0b013e3283564230. Review.

PMID:
22759740
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Gene-expression profiling in epithelial ovarian cancer.

Konstantinopoulos PA, Spentzos D, Cannistra SA.

Nat Clin Pract Oncol. 2008 Oct;5(10):577-87. doi: 10.1038/ncponc1178. Epub 2008 Jul 22. Review.

PMID:
18648354
[PubMed - indexed for MEDLINE]
10.

Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer.

Weberpals JI, Koti M, Squire JA.

Cancer Genet. 2011 Oct;204(10):525-35. doi: 10.1016/j.cancergen.2011.09.004. Review.

PMID:
22137482
[PubMed - indexed for MEDLINE]
11.

Treatment of platinum-resistant ovarian cancer.

Trimble EL, Wright J, Christian MC.

Expert Opin Pharmacother. 2001 Aug;2(8):1299-306. Review.

PMID:
11584998
[PubMed - indexed for MEDLINE]
12.

Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data.

Thames HD, Petersen C, Petersen S, Nieder C, Baumann M.

Strahlenther Onkol. 2002 Aug;178(8):411-21. Review.

PMID:
12240546
[PubMed - indexed for MEDLINE]
13.

The mutational profile of sporadic epithelial ovarian carcinoma.

Kalamanathan S, Bates V, Lord R, Green JA.

Anticancer Res. 2011 Aug;31(8):2661-8. Review.

PMID:
21778320
[PubMed - indexed for MEDLINE]
14.

The biology of ovarian cancer.

Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC.

Semin Oncol. 1998 Jun;25(3):281-304. Review.

PMID:
9633841
[PubMed - indexed for MEDLINE]
15.

Hereditary ovarian cancer: biology, response to chemotherapy and prognosis.

Safra T.

Womens Health (Lond Engl). 2009 Sep;5(5):543-53. doi: 10.2217/whe.09.40. Review.

PMID:
19702453
[PubMed - indexed for MEDLINE]
16.

Drug resistance caused by reversion mutation.

Ashworth A.

Cancer Res. 2008 Dec 15;68(24):10021-3. doi: 10.1158/0008-5472.CAN-08-2287. Review.

PMID:
19074863
[PubMed - indexed for MEDLINE]
Free Article
17.

Making the best of PARP inhibitors in ovarian cancer.

Banerjee S, Kaye SB, Ashworth A.

Nat Rev Clin Oncol. 2010 Sep;7(9):508-19. doi: 10.1038/nrclinonc.2010.116. Epub 2010 Aug 10. Review.

PMID:
20700108
[PubMed - indexed for MEDLINE]
18.

Targeted therapy for epithelial ovarian cancer.

Sharma S, Odunsi K.

Expert Opin Ther Targets. 2005 Jun;9(3):501-13. Review.

PMID:
15948670
[PubMed - indexed for MEDLINE]
19.

PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check.

Zorn KK.

Oncology (Williston Park). 2012 Feb;26(2):128-36. Review.

PMID:
22489345
[PubMed - indexed for MEDLINE]
20.

Olaparib: a promising PARP inhibitor in ovarian cancer therapy.

Chen Y, Zhang L, Hao Q.

Arch Gynecol Obstet. 2013 Aug;288(2):367-74. doi: 10.1007/s00404-013-2856-2. Epub 2013 Apr 26. Review.

PMID:
23619942
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk